Cover Image
市場調查報告書

癌症的細胞療法市場及開發平台(管線)概要

Cancer Cell Therapy Market & Pipeline Insight

出版商 KuicK Research 商品編碼 305976
出版日期 內容資訊 英文 195 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症的細胞療法市場及開發平台(管線)概要 Cancer Cell Therapy Market & Pipeline Insight
出版日期: 2014年06月18日 內容資訊: 英文 195 Pages
簡介

過去3∼5年出現了更複雜的新治療法。這就是為了治療傳統或生物醫藥品無法治療的疾病而開發的細胞療法。該市場帶來了可替代受損的組織,刺激體內修復機制以再生受損組織及臟器的希望。

本報告提供癌症細胞療法市場概要與趨勢,階段,國家,標的別開發平台概要,彙整前臨床階段的藥物數,中止·中斷的藥物簡介等。

第1章 細胞療法的簡介

  • 細胞療法的起源
  • 細胞療法結構

第2章 癌症治療的簡介

  • 癌症治療的幹細胞移植種類
  • 樹突狀細胞療法
  • 標的癌症治療

第3章 癌症的細胞療法市場概要

  • 市場概要
  • 臨床開發平台概要

第4章 全球市場趨勢

  • 推動市場的要素
  • 市場課題
  • 未來發展預測

第5章 階段,國家,標的等各適應症別癌症的細胞療法臨床實驗概要

  • 未知的階段
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一、二階段
  • 第二階段
  • 第三階段

第6章 上市的癌症細胞療法趨勢及專利分析

第7章 中斷·中止的癌症細胞療法臨床趨勢

第8章 競爭環境

  • Adaptimmune
  • Apceth
  • Argos Therapeutics Inc
  • Celgene Cellular Therapeutics
  • Cellerant Therapeutics
  • Immunicum
  • Innate Pharma
  • Innocell Corporation
  • Kite Pharma
  • Takara Bio

圖表

目錄

Since the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient.

The discovery of cell therapies has changed the notion that cancer was otherwise incurable. With the efficient capability of cell-based therapies, the number of patients being treated successfully of cancer and similar diseases has increased significantly in recent years, thus leading to the increasing popularity of cell therapy across the globe. Cell therapy for cancer treatment thus represents a paradigm shift in healthcare therapies and treatment by focusing on the basic reason of the occurrence of the disease by repairing, replacing or regenerating damaged cells of the body.

With the cell-based therapies growing significantly, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of cancer along with lack of adequate effective treatment is most likely to drive the cancer cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of cancer and other life threatening diseases.

Additionally, cell based therapies, in the next 3-4 year horizon would be increasingly used to have a better and deeper understanding of the working of genetics in the early stages of cell development. This would in turn enable scientists to understand the reasons of abnormal development of cancer cells. Thus, with the complete knowledge of genetic basis for cell development, scientists would be in a better position to develop efficient drugs and prevent the spread of cancer.

“Cancer Cell Therapy Market & Pipeline Insight” Report Highlights & Findings:

  • Cancer Cell Therapy Market Overview
  • Cancer Cell Therapy Market Dynamics
  • Clinical Pipeline by Phase, country & Target Indications
  • Cancer Cell Therapy Drugs in Pipeline: 82
  • Highest Number of Drugs in Preclinical Stage:29
  • Suspended & Discontinued Drug Profiles

Table of Contents

1. Introduction to Cell Therapy

  • 1.1. Origin of Cell Therapy
  • 1.2. Composition of Cell Therapy

2. Introduction to Cancer Therapies

  • 2.1. Types of Stem Cell Transplants for Treating Cancer
  • 2.2. Dendritic Cell Therapy
  • 2.3. Targeted Cancer Therapies

3. Cancer Cell Therapy Market Overview

  • 3.1. Market Overview
  • 3.2. Clinical Pipeline Insight

4. Global Cancer Cell Therapy Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Challenges
  • 4.3. Future Outlook

5. Cancer Cell Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications

  • 5.1. Unknown Phase
  • 5.2. Research
  • 5.3. Preclinical
  • 5.4. Clinical
  • 5.5. Phase I
  • 5.6. Phase I/II
  • 5.7. Phase II
  • 5.8. Phase III

6. Marketed Cancer Cell Therapy Clinical Insight & Patent Analysis

7. Suspended & Discontinued Cancer Cell Therapy Clinical Insight

  • 7.1. No Development Reported
  • 7.2. Discontinued
  • 7.3. Suspended

8. Competitive Landscape

  • 8.1. Adaptimmune
  • 8.2. Apceth
  • 8.3. Argos Therapeutics Inc
  • 8.4. Celgene Cellular Therapeutics
  • 8.5. Cellerant Therapeutics
  • 8.6. Immunicum
  • 8.7. Innate Pharma
  • 8.8. Innocell Corporation
  • 8.9. Kite Pharma
  • 8.10. Takara Bio

List of Figures:

  • Figure 1-1: Four Pillars of Global Pharmaceutical Industry
  • Figure 1-2: Composition of Cell Therapy
  • Figure 2-1: Cancer Therapies Overview
  • Figure 3-1: Global Cell Therapy Market (US$ Billion), 2012-2018
  • Figure 3-2: Global Cell Therapy Market by Indications, 2013
  • Figure 3-3: Global Cell Therapy Market by Region (%), 2013 & 2018
  • Figure 3-4: Global Cancer Cell Therapy Market (US$ Billion), 2012-2018
  • Figure 3-5: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 3-6: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 3-7: No Development Reported in Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 3-8: No Development Reported in Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 3-9: Discontinued Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 3-10: Discontinued Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 8-1: Adaptimmune Clinical Pipeline Insight
  • Figure 8-2: Apceth Clinical Pipeline Insight
  • Figure 8-3: Argos Therapeutics Clinical Pipeline Insight
  • Figure 8-4: Cellerant Clinical Pipeline Insight
  • Figure 8-5: Immunicum Clinical Pipeline Insight
  • Figure 8-6: Innate Pharma Clinical Pipeline Insight
  • Figure 8-7: Kite Pharma Clinical Pipeline Insight
Back to Top